{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:45:53Z","timestamp":1785321953780,"version":"3.55.0"},"reference-count":107,"publisher":"Georg Thieme Verlag KG","issue":"08","funder":[{"name":"Intramural NIDDK","award":["047053\u201312"],"award-info":[{"award-number":["047053\u201312"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The diagnostic modalities, stratification tools, and treatment options for\n                        patients with thyroid cancer have rapidly evolved since the development of\n                        the American Thyroid Association (ATA) guidelines in 2015. This review\n                        compiles newer concepts in diagnosis, stratification tools and treatment\n                        options for patients with differentiated thyroid cancer (DTC), medullary\n                        thyroid carcinoma (MTC) and anaplastic thyroid cancer (ATC). Newer\n                        developments apply precision medicine in thyroid cancer patients to avoid\n                        over-treatment in low risk disease and under-treatment in high risk disease.\n                        Among novel patient-tailored therapies are selective RET inhibitors that\n                        have shown efficacy in the treatment of MTC with limited systemic toxicity\n                        compared with non-specific tyrosine kinase inhibitors. The combination of\n                        BRAF and MEK inhibitors have revolutionized management of BRAF V600E\n                        mutant ATC. Several immunotherapeutic agents are being actively investigated\n                        in the treatment of all forms of thyroid cancer. In this review, we describe\n                        the recent advances in the diagnosis and management of DTC, MTC, and ATC,\n                        with an emphasis on novel treatment modalities.<\/jats:p>","DOI":"10.1055\/a-1089-7870","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:04:37Z","timestamp":1581379477000},"page":"562-577","source":"Crossref","is-referenced-by-count":135,"title":["Updates on the Management of Thyroid Cancer"],"prefix":"10.1055","volume":"52","author":[{"given":"Katherine A.","family":"Araque","sequence":"first","affiliation":[{"name":"Endocrinology Department, Pacific Neuroscience Institute, John Wayne\n                    Cancer Institute, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-1381","authenticated-orcid":false,"given":"Sriram","family":"Gubbi","sequence":"first","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive\n                    and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD,\n                    USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Klubo-Gwiezdzinska","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive\n                    and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD,\n                    USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"J A Fagin","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"T221","DOI":"10.1530\/ERC-18-0160","article-title":"65 Years of the Double Helix: Endocrine tumour syndromes in children and\n                    adolescents","volume":"25","author":"C Goudie","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States,\n                    1974\u20132013","volume":"317","author":"H Lim","year":"2017","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"R L Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging\n                    System for Differentiated and Anaplastic Thyroid Cancer (8th\n                    Edition): What Changed and Why?","volume":"27","author":"R M Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with\n                    thyroid nodules and differentiated thyroid cancer: The American Thyroid\n                    Association guidelines task force on thyroid nodules and differentiated thyroid\n                    cancer","volume":"26","author":"B R Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary\n                    thyroid carcinoma: The American Thyroid Association Guidelines Task Force on\n                    medullary thyroid carcinoma","volume":"25","author":"S A Wells","year":"2015","journal-title":"Thyroid"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association guidelines for management of patients with\n                    anaplastic thyroid cancer","volume":"22","author":"R C Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/modpathol.2016.65","article-title":"Ninety-four cases of encapsulated follicular variant of papillary thyroid\n                    carcinoma: A name change to noninvasive follicular thyroid neoplasm with\n                    papillary-like nuclear features would help prevent overtreatment","volume":"29","author":"L D Thompson","year":"2016","journal-title":"Modern Pathol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"N Agrawal","year":"2014","journal-title":"Cell"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1210\/jc.2002-021907","article-title":"RAS point mutations and PAX8-PPAR\u03b3 rearrangement in thyroid tumors:\n                    Evidence for distinct molecular pathways in thyroid follicular carcinoma","volume":"88","author":"M N Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/coa.13300","article-title":"Evaluating the predicted impact of changes to the AJCC\/TMN staging\n                    system for differentiated thyroid cancer (DTC): A prospective observational\n                    study of patients in South East Scotland","volume":"44","author":"K Hulse","year":"2019","journal-title":"Clin Otolaryngol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"L7","DOI":"10.1530\/ERC-17-0453","article-title":"8th edition of the AJCC\/TNM staging system of thyroid cancer:\n                    what to expect (ITCO#2)","volume":"25","author":"L Lamartina","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.12688\/f1000research.12811.1","article-title":"Recent advances in managing differentiated thyroid cancer","volume":"7","author":"L Lamartina","year":"2018","journal-title":"F1000Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.surg.2018.04.078","article-title":"Stage migration with the new American Joint Committee on Cancer (AJCC) staging\n                    system (8th edition) for differentiated thyroid cancer","volume":"165","author":"A R Shaha","year":"2019","journal-title":"Surgery"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ecl.2018.11.002","article-title":"Clinical Assessment and Risk Stratification in Differentiated Thyroid\n                    Cancer","volume":"48","author":"F Vaisman","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with\n                    Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid\n                    Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid\n                    Cancer","volume":"26","author":"B R Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"jc.2019","DOI":"10.1210\/jc.2019-00177","article-title":"Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final\n                    Follow-up","author":"R M Tuttle","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1002\/cncr.32166","article-title":"Concordance in postsurgical radioactive iodine therapy recommendations between\n                    Watson for oncology and clinical practice in patients with differentiated\n                    thyroid carcinoma","volume":"125","author":"M Kim","year":"2019","journal-title":"Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"49773","DOI":"10.18632\/oncotarget.17937","article-title":"The detection and significance of EGFR and BRAF in cell-free DNA of peripheral\n                    blood in NSCLC","volume":"8","author":"Y Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fonc.2018.00132","article-title":"The clinical utility of cell-free DNA measurement in differentiated thyroid\n                    cancer: A systematic review","volume":"8","author":"J M Fussey","year":"2018","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3349\/ymj.2015.56.3.634","article-title":"Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in\n                    papillary thyroid carcinomas","volume":"56","author":"B H Kim","year":"2015","journal-title":"Yonsei Med J"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/thy.2016.0076","article-title":"Real-Time Genomic Characterization utilizing circulating cell-free DNA in\n                    patients with anaplastic thyroid carcinoma","volume":"27","author":"V C Sandulache","year":"2017","journal-title":"Thyroid"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2017-01039","article-title":"Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients\n                    With Advanced Medullary Thyroid Carcinoma","volume":"102","author":"G J Cote","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","first-page":"235","article-title":"Liquid biopsy in thyroid cancer: New insight","volume":"12","author":"F Khatami","year":"2018","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fonc.2018.00132","article-title":"the clinical Utility of cell-Free DNa measurement in differentiated thyroid\n                    cancer: a systematic review","volume":"8","author":"J M Fussey","year":"2018","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.surg.2019.05.035","article-title":"Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in\n                    survival but not in short-term outcomes","volume":"166","author":"A Zambeli-Ljepovi\u0107","year":"2019","journal-title":"Surgery"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e11791","DOI":"10.1097\/MD.0000000000011791","article-title":"Is biopsy enough for papillary thyroid microcarcinoma?: An analysis of the SEER\n                    database 2004\u20132013 with propensity score matching","volume":"97","author":"Z Liu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/thy.2018.0462","article-title":"Active surveillance for T1bN0M0 papillary thyroid carcinoma","volume":"29","author":"T Sakai","year":"2019","journal-title":"Thyroid"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/thy.2015.0178","article-title":"A clinical framework to facilitate risk stratification when considering an\n                    active surveillance alternative to immediate biopsy and surgery in papillary\n                    microcarcinoma","volume":"26","author":"J P Brito","year":"2016","journal-title":"Thyroid"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/17446651.2018.1449641","article-title":"A clinical framework to facilitate selection of patients with differentiated\n                    thyroid cancer for active surveillance or less aggressive initial surgical\n                    management","volume":"13","author":"R M Tuttle","year":"2018","journal-title":"Exp Rev Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaoto.2017.1442","article-title":"Natural history and tumor volume kinetics of papillary thyroid cancers during\n                    active surveillance","volume":"143","author":"R M Tuttle","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surgery"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ecl.2018.10.007","article-title":"Conservative Surveillance Management of Low-Risk Papillary Thyroid\n                    Microcarcinoma","volume":"48","author":"A Miyauchi","year":"2019","journal-title":"Endocrinol Metab Clin"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2019.5350","article-title":"Active Surveillance of Low-Risk Thyroid Cancer","volume":"321","author":"K A Zanocco","year":"2019","journal-title":"JAMA"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/thy.2018.0105","article-title":"Thyroid cancer treatment choice: a pilot study of a tool to facilitate\n                    conversations with patients with papillary microcarcinomas considering treatment\n                    options","volume":"28","author":"J P Brito","year":"2018","journal-title":"Thyroid"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-med-051517-125510","article-title":"Active surveillance as first-line management of papillary microcarcinoma","volume":"70","author":"Y Ito","year":"2019","journal-title":"Ann Rev Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaoto.2018.4131","article-title":"Patient experience of thyroid cancer active surveillance in Japan","volume":"145","author":"L Davies","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surgery"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/thy.2018.0597","article-title":"Controversies, Consensus, and Collaboration in the Use of (131)I Therapy in\n                    Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid\n                    Association, the European Association of Nuclear Medicine, the Society of\n                    Nuclear Medicine and Molecular Imaging, and the European Thyroid\n                    Association","volume":"29","author":"R M Tuttle","year":"2019","journal-title":"Thyroid"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and\n                    follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"C Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03351058","article-title":"Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma","volume":"27","author":"S M Coelho","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2265.2006.02515.x","article-title":"Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma:\n                    Clinical and in vitro studies","volume":"64","author":"Y Liu","year":"2006","journal-title":"Clin Endocrinol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"A L Ho","year":"2013","journal-title":"N Eng J Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine\n                    metabolism","volume":"92","author":"C Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-06-1753","article-title":"Suppression of BRAF\/MEK\/MAP kinase pathway restores expression\n                    of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF\n                    mutant","volume":"13","author":"D Liu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"A L Ho","year":"2013","journal-title":"N Eng J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/s12885-019-5541-4","article-title":"Investigating the potential clinical benefit of Selumetinib in resensitising\n                    advanced iodine refractory differentiated thyroid cancer to radioiodine therapy\n                    (SEL-I-METRY): Protocol for a multicentre UK single arm phase II trial","volume":"19","author":"S R Brown","year":"2019","journal-title":"BMC Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"20160637","DOI":"10.1259\/bjr.20160637","article-title":"SELIMETRY\u2014a multicentre I-131 dosimetry trial: A clinical\n                    perspective","volume":"90","author":"J Wadsley","year":"2017","journal-title":"Br J Radiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fendo.2017.00312","article-title":"Updates on the management of advanced, metastatic, and radioiodine refractory\n                    differentiated thyroid cancer","volume":"8","author":"D Tumino","year":"2017","journal-title":"Front Endocrinol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic\n                    differentiated thyroid cancer: A randomised, double-blind, phase 3 trial","volume":"384","author":"M S Brose","year":"2014","journal-title":"Lancet (London, England)"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"M Schlumberger","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.6004\/jnccn.2018.0089","article-title":"NCCN guidelines insights: Thyroid carcinoma, version 2.2018","volume":"16","author":"R I Haddad","year":"2018","journal-title":"J Natl Comp Cancer Network"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beem.2017.04.014","article-title":"Novel concepts for initiating multitargeted kinase inhibitors in radioactive\n                    iodine refractory differentiated thyroid cancer","volume":"31","author":"R M Tuttle","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/ijms20061405","article-title":"PD-1 ligand expression in epithelial thyroid cancers: potential clinical\n                    implications","volume":"20","author":"S Ulisse","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti\u2013PD-1 antibody pembrolizumab in\n                    patients with advanced, PD-L1\u2013positive papillary or follicular thyroid\n                    cancer","volume":"19","author":"J M Mehnert","year":"2019","journal-title":"BMC Cancer"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/cancers10120494","article-title":"Immune gene signature delineates a subclass of papillary thyroid cancer with\n                    unfavorable clinical outcomes","volume":"10","author":"K Kim","year":"2018","journal-title":"Cancers"},{"key":"ref56","volume-title":"Trends in SEER incidence and US mortality using the joinpoint regression program\n                    1975\u20132000 with up to three joinpoints by race and sexSEER\n                    [monograf\u00eda en Internet]","author":"L Ries","year":"2003"},{"key":"ref57","first-page":"673","volume-title":"Medullary Thyroid Cancer","author":"R Elisei","year":"2019"},{"key":"ref58","first-page":"549","volume-title":"Molecular Genetics and Diagnostics of Thyroid Cancer","author":"S J Hsiao","year":"2019"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"E364","DOI":"10.1210\/jc.2012-2703","article-title":"Exomic sequencing of medullary thyroid cancer reveals dominant and mutually\n                    exclusive oncogenic mutations in RET and RAS","volume":"98","author":"N Agrawal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2006-0017","article-title":"RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine\n                    tumors","volume":"27","author":"JW B de Groot","year":"2006","journal-title":"Endocr Rev"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/hmg\/3.2.237","article-title":"Point mutation within the tyrosine kinase domain of the RET proto-oncogene in\n                    multiple endocrine neoplasia type 2B and related sporadic tumours","volume":"3","author":"C Eng","year":"1994","journal-title":"Hum Mol Genet"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1210\/jc.2007-1005","article-title":"RET genetic screening in patients with medullary thyroid cancer and their\n                    relatives: Experience with 807 individuals at one center","volume":"92","author":"R Elisei","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid\n                    cancer: A randomized, double-blind phase III trial","volume":"30","author":"S A Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"E991","DOI":"10.1210\/jc.2010-2381","article-title":"The effects of four different tyrosine kinase inhibitors on medullary and\n                    papillary thyroid cancer cells","volume":"96","author":"H H Verbeek","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2147\/OTT.S142598","article-title":"Apatinib-treated advanced medullary thyroid carcinoma: A case report","volume":"11","author":"K Chen","year":"2018","journal-title":"OncoTarg Therap"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","article-title":"A phase II trial of imatinib therapy for metastatic medullary thyroid\n                    carcinoma","volume":"92","author":"J De Groot","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"R Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients\n                    with medullary thyroid cancer","volume":"29","author":"R Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"E T Lam","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary\n                    medullary thyroid cancer","volume":"95","author":"B G Robinson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib\n                    (E7080) in advanced medullary thyroid cancer","volume":"22","author":"M Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive\n                    or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"M J Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1200\/jco.2013.31.15_suppl.6000","article-title":"Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with\n                    RAS or RET mutations: Results from a phase III study","author":"S I Sherman","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic\n                    hereditary medullary thyroid cancer","volume":"28","author":"S A Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2007.0120","article-title":"A phase II study of gefitinib in patients with advanced thyroid cancer","volume":"18","author":"N A Pennell","year":"2008","journal-title":"Thyroid"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET\u2013positive, iodine-refractory\n                    differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid\n                    with functional imaging correlation","volume":"16","author":"L L Carr","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid\n                    cancer: Results from a phase II study","volume":"26","author":"E E Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/cncr.28766","article-title":"Treatment of advanced thyroid cancer with axitinib: Phase 2 study with\n                    pharmacokinetic\/pharmacodynamic and quality-of-life assessments","volume":"120","author":"L D Locati","year":"2014","journal-title":"Cancer"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2013-3713","article-title":"A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary\n                    thyroid carcinoma: MC057H","volume":"99","author":"K C Bible","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2018.02.080","article-title":"Challenging clinically unresponsive medullary thyroid cancer: Discovery and\n                    pharmacological activity of novel RET inhibitors","volume":"150","author":"V La Pietra","year":"2018","journal-title":"Eur J Med Chem"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"V Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1200\/JCO.2018.36.15_suppl.102","article-title":"A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in\n                    patients with RET-altered cancers","author":"A E Drilon","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"V Subbiah","year":"2018","journal-title":"Cancer Discov"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/js.2018-00180","article-title":"Navigating systemic therapy in advanced thyroid carcinoma: from standard of care\n                    to personalized therapy and beyond","volume":"2","author":"S N Rao","year":"2018","journal-title":"J Endocr Soc"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-8587(16)30277-7","article-title":"Leveraging the immune system to treat advanced thyroid cancers","volume":"5","author":"J D French","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jcem.86.10.7949","article-title":"Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination","volume":"86","author":"M Schott","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3892\/or_00000391","article-title":"Pilot trial of autologous dendritic cells loaded with tumor lysate (s) from\n                    allogeneic tumor cell lines in patients with metastatic medullary thyroid\n                    carcinoma","volume":"21","author":"T Bachleitner-Hofmann","year":"2009","journal-title":"Oncol Rep"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00262-013-1505-8","article-title":"Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with\n                    metastatic CEA-expressing carcinoma","volume":"63","author":"M Bilusic","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","article-title":"Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival\n                    benefit in metastasized medullary thyroid cancer: A phase II clinical trial","volume":"13","author":"F Iten","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/RLU.0000000000000628","article-title":"Lopes FPPL et al. Is there a role for peptide receptor radionuclide therapy in\n                    medullary thyroid cancer?","volume":"40","author":"F Vaisman","year":"2015","journal-title":"Clin Nucl Med"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12885-019-5540-5","article-title":"Peptide receptor radionuclide therapy in patients with medullary thyroid\n                    carcinoma: predictors and pitfalls","volume":"19","author":"C M Beukhof","year":"2019","journal-title":"BMC Cancer"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or\n                    metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"V Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/thy.2013.0078","article-title":"Randomized safety and efficacy study of fosbretabulin with\n                    paclitaxel\/carboplatin against anaplastic thyroid carcinoma","volume":"24","author":"J A Sosa","year":"2014","journal-title":"Thyroid"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/thy.2010.0332","article-title":"Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid\n                    carcinoma","volume":"21","author":"J Akaishi","year":"2011","journal-title":"Thyroid"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.20936","article-title":"Anaplastic thyroid carcinoma: treatment outcome and prognostic factors","volume":"103","author":"E Kebebew","year":"2005","journal-title":"Cancer"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JOP.2016.012013","article-title":"Anaplastic thyroid carcinoma: Treatment in the age of molecular targeted\n                    therapy","volume":"12","author":"M E Cabanillas","year":"2016","journal-title":"J Oncol Pract"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"D M Hyman","year":"2015","journal-title":"N Eng J Med"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase II trial of everolimus in locally advanced or metastatic\n                    thyroid cancer of all histologic subtypes","volume":"24","author":"S Lim","year":"2013","journal-title":"Ann Oncol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1200\/jco.2013.31.15_suppl.6023","article-title":"A phase II study of everolimus in patients with aggressive RAI refractory (RAIR)\n                    thyroid cancer (TC)","author":"J H Lorch","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/jc.2016-3756","article-title":"Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with\n                    multimodal therapy: Results from a retrospective study","volume":"102","author":"A V Chintakuntlawar","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","article-title":"Exceptional response with immunotherapy in a patient with anaplastic thyroid\n                    cancer","volume":"22","author":"R Kollipara","year":"2017","journal-title":"Oncologist"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of\n                    anaplastic thyroid carcinoma","volume":"6","author":"P C Iyer","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1089\/thy.2016.0372","article-title":"A computer-aided diagnosis system using artificial intelligence for the\n                    diagnosis and characterization of thyroid nodules on ultrasound: initial\n                    clinical assessment","volume":"27","author":"Y J Choi","year":"2017","journal-title":"Thyroid"},{"key":"ref107","first-page":"371","article-title":"Machine learning from concept to clinic: reliable detection of braf v600e DNA\n                    mutations in thyroid nodules using high-dimensional RNA expression data","author":"J Diggans","year":"2014","journal-title":"In, Pacific Symposium on Biocomputing Co-Chairs: World\n                    Sci"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fendo.2019.00185","article-title":"Artificial Intelligence and Machine Learning in Endocrinology and Metabolism:\n                    The Dawn of a New Era","volume":"10","author":"S Gubbi","year":"2019","journal-title":"Front Endocrinol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.12659\/MSM.910088","article-title":"Identification of key pathways and genes in anaplastic thyroid carcinoma via\n                    integrated bioinformatics analysis","volume":"24","author":"S Hu","year":"2018","journal-title":"Med Sci Monit"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1148\/radiol.2019182128","article-title":"Using Artificial Intelligence to Revise ACR TI-RADS Risk Stratification of\n                    Thyroid Nodules: Diagnostic Accuracy and Utility","volume":"292","author":"B Wildman-Tobriner","year":"2019","journal-title":"Radiology"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1089-7870.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T23:41:58Z","timestamp":1661298118000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1089-7870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":107,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1089-7870","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]}}}